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Abstract
Background—As Sub-Saharan Africa transitions to a new era of universal ART, up-to-date 
assessments of HIV RNA (viral load, VL) suppression at a population level are needed to 
understand demographic and geographic sources of ongoing viremia and to inform interventions to 
optimize ART delivery. We sought to measure population viral load (VL) metrics to assess current 
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viral suppression levels and characterize demographic groups and geographic locations with high-
level detectable viremia in East Africa.
Methods—In the SEARCH HIV test-and-treat study (NCT01864683), we conducted baseline 
HIV testing (89% uptake) and HIV RNA assessments in 32 rural communities in 2013–2014 in 
Uganda and Kenya (N=303,461). We measured VL in 8,828 HIV+ adults, and defined viral 
suppression as VL<500 copies/mL. To assess geographic sources of transmission risk, we 
determined the proportion of all adults (both HIV-positive and HIV-negative) with detectable VL 
(termed ‘local prevalence of viremia’). Transmission risk ‘hotspots’ were defined as geopolitical 
subunits within communities with >5.0% local prevalence of viremia. We also assessed sero-
discordant couples, measuring the proportion in which the HIV+ partner had detectable viremia.
Findings—Viral suppression was 82% (3,427/4,202) among adults on ART, and 51% 
(4,490/8,828) among all HIV+ adults. Regional viral suppression among HIV+ adults was 48% 
(West Uganda), 45% (East Uganda) and 53% (Western Kenya). Transmission risk ‘hotspots’ 
included 1/21 W.Uganda, 0/18 E.Uganda, and 16/26 Kenya geopolitical subunits. In Uganda, sero-
discordancy was 3.1% (492 discordant/16,023 total couples). In 58% of discordant couples, the 
HIV+ partner was viremic (14% had VL>100,000). In Kenya, sero-discordancy was 10.0% 
(859/8,616 total couples). In 53%, the HIV+ partner was viremic (15% with VL>100,000).
Interpretation—Prior to the 2013–2014 start of the SEARCH trial, 51% of East African HIV+ 
adults had viral suppression, reflecting ART scale-up efforts to date. However, geographic 
‘hotspots’ of potential HIV transmission risk as well as detectable viremia among sero-discordant 
couples warrant intensified interventions.
Funding—US National Institute of Allergy and Infectious Diseases (NIAID), National Institutes 
of Health. President’s Emergency Plan for AIDS Relief (PEPFAR).
Keywords
HIV antiretroviral therapy (ART); population HIV viral load; hotspots; transmission risk; sero-
discordant couples
Introduction
As Sub-Saharan Africa transitions to a new era in which ART is offered to all HIV-positive 
persons regardless of CD4+ cell count,1–3 up-to-date assessments of HIV RNA (viral load, 
VL) suppression at a population level4–7 can be informative. Viral suppression is the final 
metric of the UNAIDS 90-90-90 initiative 8 (90% diagnosed/90% on ART/90% virologically 
suppressed), which aims at maximizing HIV diagnosis, treatment and viral suppression to 
improve individuals’ health and substantially reduce the potential for HIV transmission.9, 10 
As countries begin expanding to universal ART coverage, insights into population-level viral 
suppression can assist treatment and prevention programs by revealing demographic groups 
with the highest burden of detectable VL. Population VL analyses can also characterize the 
geographic distribution of persons with detectable VL and identify ‘hotspots’ of potential 
HIV transmission risk—areas where persons with HIV or persons with detectable viremia 
are prevalent.11 Along with behavioral risk factor data, these insights can help programs 
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efficiently target resources to the people and regions most in need of intensified HIV 
program support.
The scale-up of HIV testing and CD4-guided ART has proceeded at different paces in Sub-
Saharan African nations,12 leading to wide-ranging estimates of population-level viral 
suppression. UNAIDS has estimated that 32% of Sub-Saharan HIV+ adults overall are 
virally suppressed.13 However, in one recent study from Botswana—one of the first 
providers of widescale HIV testing and treatment—population viral suppression was 
estimated to be far higher at 70%.14 In contrast, in two smaller studies in East Africa, viral 
suppression was in the 40–50% range,15, 16 and in a study from Swaziland, was estimated at 
35%.17 Other VL surveys have been limited in size, and several have been derived from 
persons already in HIV care rather than from comprehensive population samples that include 
persons unaware of their HIV diagnosis or not yet in HIV care. More broadly, 
comprehensive measures of VL at a population level have not been frequently conducted due 
to logistic challenges with population sampling, barriers to VL collection, and cost of VL 
testing.18
Sero-discordant couples are a high priority population in Sub-Saharan Africa: it is well 
established that intensive treatment and prevention interventions should be offered to 
minimize HIV transmission risk. However, data that make the crucial distinction between 
sero-discordant couples in which the HIV+ partner is virologically suppressed versus 
viremic are not widely available. Because HIV transmission risk is directly related to levels 
of viremia,9, 19, 20 understanding the epidemiologic prevalence of viremia within sero-
discordant couples is a high priority for developing optimum interventions for this 
population.
The SEARCH Study (Sustainable East Africa Research in Community Health: 
NCT01864683) is a cluster randomized trial in Uganda and Kenya of a universal HIV test-
and-treat strategy combining universal HIV testing campaigns with efficient universal ART 
delivery to all HIV-infected persons; SEARCH is assessing the impact of this test-and-treat 
approach on HIV incidence and secondary individual and community-level health outcomes. 
During the baseline population assessment in the SEARCH Study, we sought to determine 
the current state of viral suppression in rural regions of Uganda and Kenya that are rapidly 
scaling up HIV testing and ART provision. We also sought to assess demographic factors 
(including sero-discordancy) as well as geographic factors influencing HIV risk related to 
detectable viremia in these regions.
Methods
Study Design and Population
The Sustainable East Africa Research for Community Health Study 
(SEARCH:NCT01864603) is a multi-national cluster-randomized trial of a universal HIV 
‘test-and-treat’ intervention strategy versus standard country-guided HIV control strategy 
across 32 communities (approximately N=10,000 each) in rural West Uganda, East Uganda, 
and Homa Bay and Migori Counties in Kenya. Communities were selected using detailed 
criteria previously reported,21 including rural setting, approximate population of 10,000 
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persons, and within the catchment area of a President’s Emergency Plan for AIDS Relief 
(PEPFAR) supported HIV clinic. Ugandan and Kenyan communities were comprised of 
geopolitical subunits (‘parishes’ in Uganda; ‘sublocations’ in Kenya).
This study was approved by ethical review boards of Makerere University, Uganda National 
Council of Science and Technology (Kampala, Uganda), Kenya Medical Research Institute 
(Nairobi, Kenya), and the University of California, San Francisco (USA). All participants 
provided verbal informed consent in their preferred language.
Procedures
As previously described, SEARCH performed a household census to enumerate and collect 
demographic information from all residents of 32 study communities. This survey collected 
age, gender, marital and occupational status, history of binge alcohol drinking (≥6 drinks at 
one time), and self-reported estimates of household wealth.21 We performed population-
wide HIV testing (using a hybrid approach of community health campaigns [CHCs], 
followed by home-based testing of persons who did not attend the campaigns) and baseline 
HIV RNA measurements for adults in the 32 communities.21 We classified participants as on 
or off ART by their self report. In a random subset of patients, self-reported ART status was 
confirmed by examining clinic records, which note ART initiation and refill dates.
In HIV-positive participants, plasma was processed by study staff from fingerprick or venous 
capillary blood as reported previously.6, 22 Plasma HIV RNA levels were determined using 
commercial real-time PCR assays at accredited laboratories at the University of California, 
San Francisco, the Joint Clinical Research Centers (JCRC), Uganda, and at the Centers for 
Disease Control (CDC) HIV-R laboratory in Kisumu, Kenya. Reduced plasma input volumes 
for capillary sampling (70 uL) increased the lower limit of quantitation (LLOQ) to 500 
copies/mL in 29/32 communities, and to 1000 copies/mL in the remaining 3/32 
communities.
Analysis
To have a consistent cross-community definition of viral suppression, we excluded the 3/32 
SEARCH communities where VL assay LLOQ was 1000 copies/mL, and included the 29/32 
communities where VL assay LLOQ was 500 copies/mL. We analyzed adults (≥15 years) 
who were ‘stable’ community residents, defined by self-report as living in the community 
for ≥6 months in the preceding year.
We calculated viral suppression (defined as VL<500 copies/mL) among all HIV+ persons 
self-reporting ART use, reflecting one aspect of ART program effectiveness. We further 
characterized VL metrics among all HIV+ persons (regardless of ART use) as an overall 
assessment of the success of ART penetration in Uganda/Kenya under national guidelines, 
which at that time made ART available to persons with CD4<350/uL. VL measurements 
were categorized into five strata: suppressed (VL<500 copies/mL), 500–1,000, 1,000–
10,000, 10,000–100,000, and >100,000. Median and mean log10(VL) were calculated 
within each community and in each region (W. Uganda/E. Uganda/ Kenya).
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To assess risk factors for potential HIV transmission among all HIV+ adults regardless of 
ART use, we evaluated individual-level predictors of having a detectable VL. We used 
logistic regression accounting for household-level clustering to assess predictors including 
geographic region (W. Uganda/E. Uganda/ Kenya), age stratum, gender, marital status 
(married vs. not married), occupation (farmer/agricultural vs. other), binge alcohol drinking 
(yes vs. no), household wealth quintile (from principal component analysis derived from a 
household assets questionnaire), and HIV testing location (community health campaign vs. 
at home). Adjusted odds ratios for each predictor were calculated using a model containing 
all variables.
To characterize transmission risk existing in any community for an encounter occurring in 
that community, we estimated the ‘local prevalence of viremia’ in three steps: (1) measuring 
the fraction of HIV-positive stable adult community residents with a measured VL who had 
detectable viremia (≥500 copies/mL), (2) multiplying this fraction by the total number of 
stable adult residents who tested HIV-positive in the community, and (3) dividing this 
estimate of viremic adults by the total adult stable resident population with a measured HIV 
status (both HIV-positive and HIV-negative). This method considered adults with missing 
VL values and HIV serostatus values as missing completely at random. We estimated local 
prevalence of viremia in this manner for geopolitical subunits within communities, and for 
communities overall. We compared median local prevalence of viremia of communities 
within each region using Wilcoxon rank-sum tests.
HIV transmission risk ‘hotspots’ were assessed as present or absent based on whether any 
geopolitical subunit within a community had a local prevalence of viremia of ≥5.0%.
HIV sero-discordant couples with a viremic HIV-positive partner paired with an HIV-
negative partner are at high risk for potential HIV transmission,23 and warrant urgent 
treatment and prevention interventions. To study the magnitude and characteristics of this 
population in Uganda and Kenya, we assessed self-identified male-female household 
couples. Couples were either sero-concordant (two HIV-negative persons, or two HIV-
positive persons), or sero-discordant (HIV-positive person with HIV-negative person). In 
discordant couples, furthermore, an HIV-positive partner could have detectable viremia or be 
virally suppressed. In each region, we tabulated couples of each type resulting from 
combinations of male and female gender with HIV status. For discordant couples with a 
viremic HIV+ partner, we assessed how frequently the viremic partner had a VL>100,000—
a level denoting the highest potential for transmission.20, 23
Role of the Funding Source
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
Overall, 274,040 stable residents were enumerated in 29 study communities from April 2, 
2013, to June 8, 2014, including 132,030 adults (Fig. 1; Uganda N=79,682, Kenya 
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N=52,348) and 142,010 children. Among adults, we determined HIV status in 
117,711/132,030 (89%). Overall, 11,964 adults were HIV-positive (6.3% prevalence 
[2,096/33,424] in West Uganda, 3.2% [1,238/38,446] in East Uganda, and 18.6% 
[8,510/45,646] in Kenya), 66% [7,848/11,964] were female, 54% [6,413/11,964] worked in 
agriculture, and 70% [8,315/11,964] were married. Overall, 76% [9,090/11,964] of 
individuals were diagnosed with HIV at community health campaigns, and 24% via home-
based tracking (Table 1). Demographic data for individuals within each individual 
community are given in the appendix (Page 1).
Among HIV+ adults, we determined VL in 8,828/11,964 (74%). We were unable to 
determine VL in 3,136/11,964 (26%) of tested HIV+ persons (Fig. 1). Top reasons were (1) 
logistic sample problems (n=2,051/3,136 [65% of missing VLs]) including barriers related 
to staffing, transportation, reagents/materials, and sporadic sample processing problems, (2) 
no sample collected during health campaign (n=21), (3) no sample collected during home-
based tracking (n=550), (4) participants declined sample collection (n=204/3,136 [6.5%]), 
(5) sample loss (n=112/3,136 [3.6%]), and (6) delayed HIV ascertainment preventing VL 
collection (n=198/3,136 [6.3%]). Demographic characteristics were similar between persons 
with (n=8,828) vs. without a VL (n=3,136, Table 1).
Among HIV+ adults on ART by self-report, VL was suppressed in 82% (3,427/4,202; Table 
2). Overall, among HIV+ adults with a measured VL, viral suppression was 51% 
(4,490/8,828; Table 2). Across study regions, VL was low (500–10,000 c/mL), moderate 
(10,001–100,000 c/mL) and high (>100,000 c/mL) in 14.9% [1,318/8,828], 21.7% 
[1,914/8,828], and 12.5% [1,106/8,828] of HIV+ individuals, respectively. In West Uganda, 
48% [881/1,827] of HIV+ adults overall and 84% [568/675] of adults on ART had 
suppressed VL. In East Uganda, 45% [516/1,147] of HIV+ adults overall and 75% [345/458] 
of those on ART were suppressed. In Kenya, 53% [3,093/5,854] of HIV+ adults overall and 
82% [2,514/3,069] of those on ART were suppressed (Table 2). Viral suppression among 
HIV+ persons ranged in geopolitical subunits of communities from 27.2%-61.1% in West 
Uganda, 26.0%-61.5% in East Uganda, and 41.9%-63.9% in Kenya (Table 3). HIV+ adults 
with VL>100,000 copies/mL—at highest risk for potential HIV transmission attributable to 
VL—were 11% [198/1,827] in West Uganda, 16% [180/1,147] in East Uganda, and 12% 
[728/5,854] in Kenya (Table 2).
We examined individual-level predictors of detectable viremia among HIV+ adults to assess 
factors that could raise HIV transmission risk. In multivariable analysis, we found that 
region (E. Uganda: odds ratio (OR) 1.49 [95% CI, 1.29–1.72] vs. Kenya), younger age (OR 
4.07 [3.21–5.17] for age 21–30 vs. >60), male gender (OR 1.48 [1.34–1.63]), married status 
(OR 1.19 [1.08–1.32] vs. single/divorced), binge alcohol drinking (OR 1.62 [1.28–2.05]) 
and lower wealth (OR 1.52 [1.32–1.77] for lowest vs. highest quintile) independently 
predicted detectable viremia among HIV+ adults (Table 4). Individuals diagnosed via home-
testing were more frequently viremic than persons tested at community health campaigns 
(OR 1.41 [1.26–1.57]; Table 4).
Local prevalence of viremia (percentage of all adults [regardless of HIV status] estimated to 
have detectable VL) was higher in Kenya communities (median 8.3%, range 3.0%-14.2%) 
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vs. West Uganda (median 3.0%, range 1.3%-5.6%; p=0.0007; Table 3). Local prevalence of 
viremia was also higher in Kenya vs. East Uganda (median 1.7%, range 0.5%-3.1%, 
p=0.0001), and higher in West Uganda vs. East Uganda (median 3.0% vs. 1.7%, p=0.002).
There was substantial geographic variation in community VL metrics: in West Uganda, 
estimates of local prevalence of viremia varied >4-fold across the geopolitical subunits 
comprising communities (range 1.3% [Rwengwe parish, Nsiika] to 5.6% [Magambo parish, 
Rugazi]; Table 3). In East Uganda, although local prevalence of viremia was lower overall, it 
still varied >6-fold (range 0.5% [Oboliso parish, Kameke] to 3.1% [Merikit perish, 
Merikit]). Finally, in Kenya, local prevalence of viremia also ranged >4-fold (range 3.0% 
[Bware] to 14.2% [Uterere sublocation, Kisegi; Table 3).
Notable geographic juxtaposition of communities with higher and lower local prevalence of 
viremia was evident. Figure 2 shows community locations and estimates of local prevalence 
of viremia. The Kenyan community with the highest viremia prevalence (Othoro, 11.2%) 
closely borders one of the lowest viremia prevalence communities (Bware, 2.7%; Fig. 2C).
HIV transmission risk ‘hotspots’ (i.e., geographic regions with higher local prevalence of 
viremia) denote higher HIV transmission risk, because random contact in these regions 
signifies likelier exposure to a person with detectable virus. Overall, 3/21 parishes in 
Western Uganda (e.g., Magambo, Rugazi; Table 3), 0/18 parishes in East Uganda, and 23/26 
sublocations in Kenya were transmission risk hotspots (Table 3). In Kenya, the highest local 
prevalence of viremia was 14.2%, seen in Uterere (Kisegi; Table 3).
To assess detectable viremia and HIV transmission risk within sero-discordant couples, we 
enumerated 25,490 couples (Fig. 3A). Of these, 1,351 (5.3%) were sero-discordant (i.e., 
composed of one HIV-positive and one HIV-negative partner). In 742/1,351 sero-discordant 
couples (55%), the HIV+ partner had a detectable VL, indicating immediate transmission 
risk (Fig. 3A). In Uganda, 492/16,023 (3.1%) of couples were sero-discordant. In 58% of 
these sero-discordant couples, the HIV+ partner was viremic, and in 15% the viremic partner 
had VL>100,000 c/mL, indicating marked transmission risk (Fig 3B–C). In Kenya, sero-
discordancy was >3-fold more common than in Uganda, occurring in 859/8,616 (10.0%) of 
couples (Fig. 3D). In 53% of the sero-discordant couples, the HIV+ partner was viremic, and 
13% had a viremic partner with VL>100,000 c/mL.
Discussion
We conducted a cross-sectional analysis of population-level HIV RNA levels during the 
baseline assessment for a test-and-treat study (SEARCH) in rural Uganda and Kenya. We 
found 51% of HIV-infected adults had viral suppression, reflecting the impact of CD4-
guided ART scale-up. Conversely, nearly half of all HIV-infected adults had detectable 
viremia, creating risk for potential HIV transmission. We also identified geopolitical units 
where 5–10% of the entire adult population had detectable VL, representing ‘hotspots’ of 
potential HIV transmission risk. Finally, we found that in over half of sero-discordant 
couples, the HIV+ partner had detectable VL. These data—the largest ever population-
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sampled viral load survey in East Africa—provide an up-to-date view of the HIV epidemic 
as a new era of universal ART eligibility begins.
Our finding that 51% of HIV+ persons have viral suppression contrasts the 32% aggregate 
Sub-Saharan estimate by UNAIDS.13 Some data comprising the UNAIDS study predated 
2013, and may not fully reflect current progress in ART scale-up. A recent report from 
Botswana reported even higher viral suppression among 3,596 HIV+ adults out of 12,610 
sampled. They found 70% of HIV+ individuals had viral suppression (VL<400 c/mL).14 
Botswana began ART scale-up earlier than many other countries using CD4-restricted 
guidelines. Because of its successful HIV testing program, and successful ART programs 
achieving >95% viral suppression, Botswana has reached this impressive population viral 
suppression threshold.
Two smaller East African studies also estimated viral suppression. In a 2012 household 
survey in Homa Bay County, Kenya, (N=1,397; HIV prevalence, 24%), viral suppression 
(VL<1000 c/mL) was 39.7%.15 A study from Rwanda using electronic medical record data 
(N=3,066 patients on ART) found 82.1% virologically suppressed (VL<40 c/mL). Modeling 
the HIV care cascade, authors estimated that 106,371/204,889 (52%) of HIV+ Rwandans 
were virologically suppressed. Our data span 2013–2014, offering recent estimates from 
East Africa, and relied on comprehensive population sampling rather than being restricted to 
selected households or patients already in HIV care. Together, these studies are consistent 
with an emerging consensus that viral suppression in East Africa is most likely in the 40–
50% range currently.
We found detectable VL (i.e., viremia) in nearly half of the HIV+ adults we studied in 
Uganda and Kenya. Predictors of detectable viremia (and therefore HIV transmission) 
included younger age, male gender, married status, and lower household wealth. Being HIV-
tested at home rather than at a community health fair also predicted viremia. This may be a 
proxy characteristic for non-health-seeking behavior. Binge alcohol drinking was also 
predictive of detectable viremia, consistent with an emerging literature linking this practice 
to both ART non-adherence24 as well as virologic non-suppression in Sub-Saharan Africa.25 
Our analysis, which did not adjust for self-reported ART use, suggests that somewhere along 
the HIV care cascade, these populations are less likely to engage in care, receive ART, and 
adhere to therapy. These risk groups are well-documented in the literature to face both 
structural and behavioral barriers to linkage and retention in care.26
In addition to demographic risk factors for detectable viremia, we also assessed the 
geographic distribution of viremic individuals. There is no universally accepted definition of 
a ‘hotspot,’ and HIV transmission risk may be predominantly influenced by sexual or 
injection drug use patterns. However, hotspot analysis has helped design both prevention and 
treatment strategies for HIV27, 28 and other diseases like tuberculosis.29
In this study, by assessing VL values in geographic units within a large population, 
‘hotspots’ of higher prevalence of viremia were seen in regions with HIV prevalence ranging 
from 6.3% (West Uganda) to 18.6% (Kenya).21 Thus, regional and community-specific data 
can reveal important features of local epidemics within areas of generalized epidemics. 
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Relying solely on aggregated administrative data, especially in lower-prevalence regions, 
may fail to reveal small locations of substantially higher potential transmission risk 
embedded within larger areas, underscoring the value of geographic analysis to identify 
intervention targets.
Reasons for ‘hotspots’ likely differ between communities, and will require local study. In 
prior studies, ‘hotspots’ have tracked closely with transportation routes,11, 30 and have 
clustered within occupations such as fisherfolk and sex workers.28 It is also likely that 
markets, bars, and other locations influence geographic risk. Detailed analyses of our 
communities with high viremia prevalence are underway, to characterize factors influencing 
‘hotspot’ regions, including geography, transport routes, locations of HIV care provision, 
and ART coverage. Approaches like ours that combine a census with community-based HIV 
testing, along with behavioral and demographic data, provide a powerful approach to 
identifying risk locations, allowing for targeted interventions. These could include enhanced 
HIV testing services, for example, at locations with high viremia prevalence, or enhanced 
ART care services such as community ART groups or community ART delivery points in 
communities with high local prevalence of viremia.
Alongside geographic risks, we also demonstrate marked risk within HIV sero-discordant 
Ugandan and Kenyan couples. Over half of sero-discordant couples had a partner with 
detectable viremia, and 15% of these had VL>100,000, signifying immediate high risk for 
potential HIV transmission.31 Although behavioral interventions can mitigate this risk, the 
risk of transmission when VL>100,000 c/mL may be 8-fold higher than when VL=1,000 
c/mL.32 Notably, the number of viremic male partners was similar to viremic female 
partners, indicating that transmission risk is driven by both genders. Although guidelines for 
management of discordant couples have recommended interventions including regular HIV 
testing and counseling, condom use, and screening for sexually-transmitted infections, these 
have been challenging to implement. Newer interventions including pre-exposure 
prophylaxis (PrEP) for HIV-negative individuals, and immediate ART for HIV-positive 
individuals in sero-discordant couples, could have substantial impact given these 
challenges.3
Our study had certain limitations. First, we did not ascertain HIV status on all individuals; 
however, we did achieve 89% overall adult testing coverage. Further, community health 
campaigns one year after baseline successfully tested 50% of those who did not test in the 
baseline year; these adults had a similar HIV prevalence (9.7%) to baseline testers.33 
Second, among HIV-positive individuals, our population sample did not measure VL on all 
HIV+ individuals, missing 26% mainly due to sporadic logistic problems during field 
conditions. While informative missingness is a possible source of bias, demographic 
characteristics were similar between persons with and without measured VLs. Third, our 
geographic analysis was done at parish and community levels—we thus could not assess 
person-to-person relationships and more granular ‘hotspots’ centered around locations of 
employment, schools, or social activities. Fourth, our sero-discordant couple analyses only 
assessed self-reported household relationships. We thus could not evaluate undeclared or 
secondary partnerships that also influence transmission risk.
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In summary, in a large population-based study in East Africa, we found evidence that ART 
scale-up has achieved measurable impact on levels of viral suppression. Nevertheless, nearly 
half of HIV+ adults are viremic, geographic ‘hotspots’ of transmission risk exist, and sero-
discordant couples harbor substantial levels of potential HIV transmission risk. Our data 
advance a comprehensive up-to-date view of the East African HIV epidemic as the era of 
universal ART begins.
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Research in Context
Evidence before this study
Evidence has accumulated that HIV antiretroviral therapy improves the health of all HIV-
infected persons regardless of CD4+ T-cell count, and dramatically lowers the potential 
for HIV transmission. Global guidelines now endorse universal ART, and Sub-Saharan 
Africa is transitioning to a new era in which countries are scaling up ART to all HIV-
positive persons. In tandem, UNAIDS conceptualized the ‘90-90–90’ initiative (aiming 
for 90% of HIV-positive persons to be diagnosed, 90% of diagnosed persons to be on 
ART, and >90% of persons on ART to achieve viral suppression), translating to a 
population viral suppression of 73%. However, very few population level assessments of 
viral load metrics have been performed, particularly in East Africa, due to difficulties 
sampling a broad population, logistics of phlebotomy and the current costs of viral load 
testing. This type of information from East Africa is crucial for understanding where we 
stand as we initiate the new era of universal ART. This information is needed to set HIV 
program priorities, match funding to areas of greatest need, and understand ongoing 
drivers of circulating viremia.
We searched PubMed, and public documents and reports from UNAIDS, WHO and the 
CDC using combinations of search terms including ―population viral load,‖ ―East 
Africa,‖ ―antiretroviral therapy,‖ and ―universal ART‖ in English language sources up 
to October 1, 2016. Few available estimates of viral suppression in East Africa exist; 
current reports are derived from ART program data that only account for patients already 
in HIV care, rather than patients who are HIV-positive but not yet diagnosed or in care. 
Other available estimates include population-level data but are from prior years, have 
limitations in sample size and breadth of the population assessed, and do not enumerate 
specific groups or types of geographic locations at risk for having elevated levels of 
detectable HIV RNA. Limited data are available about the current state of the HIV 
epidemic in East Africa as the era of universal ART begins.
Added value of this study
Within a large-scale East African population-based cluster-randomized clinical trial of a 
universal HIV test-and-treat intervention (the SEARCH Study) that is ongoing across 32 
communities in Uganda and Kenya (approximately 10,000 persons per community), we 
performed what is to our knowledge the largest ever assessment of HIV viral loads of 
general populations in Uganda and Kenya, two East African countries rapidly scaling up 
ART and adopting universal therapy programs. We found that 51% of the East African 
population assessed had viral suppression—higher than previous UNAIDS estimates of 
30–35%, but lower than a recent estimate of 70% from Botswana in Southern Africa. We 
also found specific geographic areas with elevated levels of viremia: ‘hotspots’ that are 
likely to have higher risk of ongoing HIV transmission. Additionally, we found that East 
African discordant couples (male-female pairs in which one person is HIV-positive, and 
one person is HIV-negative) have very high rates of detectable viral load, and thus are 
harboring substantial risk for HIV transmission.
Implications of all the available evidence
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In this largest ever cross-sectional description of the East African HIV epidemic, we find 
that over half of adults are virally suppressed—evidence that ART scale-up is continuing 
successfully. However, we also find ‘hotspots’ of risk: geographic locations and large 
numbers of discordant couples with elevated levels of viremia. These locations and 
populations at risk will require dedicated interventions.
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Figure 1. CONSORT Diagram
Selection of 8,828 adults for analysis who had stable residence in study communities, 
underwent HIV testing, and had HIV RNA level (viral load) determined. Three of 32 
communities in the SEARCH Study were excluded because viral load testing utilized a 
higher lower limit of quantitation (<1,000 copies/mL) than was used study-wide (<500 c/
mL). Children were excluded. HIV status was not determined in some individuals. Of HIV 
sero-positive individuals, viral load results were unavailable in a subset of participants.
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Figure 2. Local community prevalence of viremia by region
(A) Geographic maps showing locations of West Uganda study communities [map + inset 
map]. For each community, the local prevalence of viremia is indicated (% of adults 
[regardless of HIV status] who had HIV viremia). (B) Maps showing East Uganda 
community locations and local prevalence of viremia. (C) Maps showing Kenya community 
locations and local prevalence of viremia.
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Figure 3. Viral suppression by sero-discordancy characteristics of male-female couples
(A) Overall numbers of male-female couples [n=25,490] defined by the male and female 
partner being either HIV-negative, HIV-positive with VL>500 c/mL, or HIV-positive with 
VL>500 c/mL. Sero-discordant couples with lower risk (light blue boxes) and higher risk 
(red boxes) are indicated. Analogous tables of sero-discordant couples in (B) West Uganda 
[n=7,682 couples], (C) East Uganda [n=9,192 couples], and (D) Kenya [8,616 couples] are 
shown.
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Table 1
Characteristics of Ugandan and Kenyan HIV-Positive Adults with and without Measured HIV RNA Levels 
(n=11,964)
Characteristic Total(n = 11,964)
With VL Result
(n = 8,828)
No VL Result
(n = 3,136)
Region
    West Uganda 2,156 (18.0) 1,827 (20.7) 329 (10.5)
    East Uganda 1,278 (10.7) 1,147 (13.0) 131 (2.4)
    Kenya 8,530 (71.3) 5,854 (66.3) 2,676 (85.3)
Gender
    Female 7,848 (65.6) 5,843 (66.2) 2,005 (63.9)
    Male 4,116 (34.3) 2,985 (33.8) 1131 (36.1)
Occupation
    Farmer/agricultural work 6,413 (53.6) 5,133 (58.1) 1,280 (40.8)
    Non-agricultural workA 5,551 (46.4) 3,695 (41.9) 1,856 (59.2)
Age
    15 to 20 years 534 (4.5) 400 (4.5) 134 (4.3)
    21 to 30 years 3,458 (28.9) 2,427 (27.5) 1,031 (32.9)
    31 to 40 years 3,830 (32.0) 2,839 (32.2) 991 (31.6)
    41 to 50 years 2,391 (20.0) 1,821 (20.6) 570 (18.2)
    51 to 60 years 1,201 (10.0) 935 (10.6) 266 (8.5)
    > 60 years 550 (4.6) 406 (4.6) 144 (4.6)
Marital status
    Married 8,315 (69.6)B 6,075 (68.9)C 2,240 (71.6)D
    Single or divorced 3,633 (30.4) 2,743 (31.1) 890 (28.4)
Household wealth
    1st quintile (lowest wealth) 1,949 (16.6)E 1,461 (16.7) 488 (16.2) G
    2nd quintile 1,898 (16.1) 1,502 (17.2) 396 (13.1)
    3rd quintile 2,244 (19.1) 1,670 (19.1) 574 (19.1)
    4th quintile 2,609 (22.2) 1,933 (22.1) 676 (22.4)
    5th quintile (highest wealth) 3,057 (26.0) 2,179 (24.9) F 878 (29.2)
Mode of HIV testing
    At community health campaign 9,090 (76.1)H 6,822 (77.3) I 2,268 (72.5)J
    At home, via home-based testing 2,863 (23.9) 2,003 (22.7) 860 (27.5)
NOTE.
A
Fisher (n=1,555 [28.0%]), shopkeeper/vendor (n=1,274 [22.9%]), teacher (n=225 [4.1%]), transportation (n=157 [2.8%]), other (n=1,636 
[29.5%]), not provided (n=13 [0.2%]), no job (n=691 [12.5%]).
B–J
Frequencies: B: 11,948; C : 8,818; D: 3,130; E: 11,757; F: 8,745; G: 3,012; H: 11,953; I: 8,825; J: 3,128.
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Table 4
Predictors of Detectable HIV RNA among HIV-Positive Adults (n=8,828)
Characteristic aOR (95% CI) p-value
Region
    West Uganda 1.09 (0.97–1.23) 0.16
    East Uganda 1.46 (1.26–1.69) < 0.0001
    Kenya Ref. —
Age (years)
    15 to 20 7.05 (5.11–9.73) < 0.0001
    21 to 30 4.04 (3.18–5.12) < 0.0001
    31 to 40 2.14 (1.70–2.70) < 0.0001
    41 to 50 1.44 (1.14–1.83) 0.002
    51 to 60 1.13 (0.87–1.45) 0.36
    >60 Ref. —
Gender
    Female Ref. —
    Male 1.42 (1.29–1.57) < 0.0001
Marital Status
    Married 1.20 (1.08–1.33) 0.0006
    Single or divorced Ref. —
Occupation
    Farmer Ref. —
    Non-farmer 0.94 (0.86–1.03) 0.18
Wealth
    1st quintile (lowest wealth) 1.52 (1.31–1.76) < 0.0001
    2nd quintile 1.27 (1.10–1.47) 0.0013
    3rd quintile 1.10 (0.95–1.26) 0.19
    4th quintile 1.11 (0.97–1.27) 0.13
    5th quintile (highest wealth) Ref. —
Binge alcohol drinking
    No Ref. —
    Yes 1.62 (1.28–2.05) < 0.0001
SEARCH testing mode
    At community health campaign Ref. —
    At home-based testing 1.62 (1.28–2.05) < 0.0001
NOTE. aOR, adjusted odds ratio
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